^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mupadolimab (CPI-006)

    i
    Other names: CPI 006, CPX006, CPX 006, CPI-006, CPI006, CPX-006
    Associations

    News

    Trials
    Company:
    Angel Pharma, Corvus Pharma
    Drug class:
    CD73 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (clinicaltrials.gov)
    P1, N=117, Completed, Corvus Pharmaceuticals, Inc. | Active, not recruiting --> Completed | N=378 --> 117 | Trial completion date: Dec 2025 --> Feb 2023 | Trial primary completion date: Dec 2023 --> Dec 2022
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • ciforadenant (CPI-444) • mupadolimab (CPI-006)
    over2years
    CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (clinicaltrials.gov)
    P1, N=378, Active, not recruiting, Corvus Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • ciforadenant (CPI-444) • mupadolimab (CPI-006)
    over2years
    CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (clinicaltrials.gov)
    P1, N=378, Recruiting, Corvus Pharmaceuticals, Inc. | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Mar 2022 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • ciforadenant (CPI-444) • mupadolimab (CPI-006)
    3years
    Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: Clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC) (SITC 2021)
    Background Mupadolimab (mupa) is a humanized FcγR binding-deficient IgG1 anti-CD73 antibody that has agonistic properties.1 CD73 is involved in production of adenosine and in cellular trafficking...Cross blocking and cellular internalization studies showed that mupa is distinct from other anti-CD73 antibodies such as MEDI9447 and AD2...This activity supports a strategy to combine mupa with pembrolizumab to enhance both humoral and cellular immunity in the treatment of viral associated cancers such as HPV+HNSCC, and viral infections. Trial Registration NCT03454451
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    CD73 (5'-Nucleotidase Ecto) • CD69 (CD69 Molecule) • NT5E (5'-Nucleotidase Ecto) • SDC1 (Syndecan 1)
    |
    CD73 expression
    |
    Keytruda (pembrolizumab) • oleclumab (MEDI9447) • mupadolimab (CPI-006)